DiaMedica Therapeutics Inc. (DMAC): Price and Financial Metrics
GET POWR RATINGS... FREE!
DMAC Stock Price Chart Interactive Chart >
DMAC Price/Volume Stats
| Current price | $1.30 | 52-week high | $4.82 |
| Prev. close | $2.02 | 52-week low | $1.15 |
| Day low | $1.15 | Volume | 2,393,572 |
| Day high | $1.31 | Avg. volume | 79,161 |
| 50-day MA | $2.30 | Dividend yield | N/A |
| 200-day MA | $3.06 | Market Cap | 34.38M |
DiaMedica Therapeutics Inc. (DMAC) Company Bio
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Latest DMAC News From Around the Web
Below are the latest news stories about DiaMedica Therapeutics Inc that investors may wish to consider to help them evaluate DMAC as an investment opportunity.
Maxim Group Thinks Diamedica Therapeutics’ Stock is Going to RecoverIn a report issued on February 2, Jason McCarthy from Maxim Group maintained a Buy rating on Diamedica Therapeutics (DMAC – Research Report), with a price target of $6.00. The company's shares closed last Friday at $2.77, close to its 52-week low of $2.20. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. |
DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial OfficerMINNEAPOLIS, February 02, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Dominic Cundari as Chief Commercial Officer. In this role, Mr. Cundari will be focused primarily on the commercial planning, positioning and launch preparations for DM199 in acute ischemic stroke. |
DiaMedica Therapeutics to Present Research at International Stroke ConferenceMINNEAPOLIS, January 25, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference being held in New Orleans, LA and Virtually from February 9 – 11, 2022. For information about the event, visit: https://professional.heart.org/en/meetings/int |
DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical OfficerMINNEAPOLIS, January 05, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Kirsten Gruis, M.D. as Chief Medical Officer. Dr. Gruis is a board-certified neurologist with 20 years of experience in both clinical medicine and drug development in large and small biopharmaceutical companies. |
DMAC Price Returns
| 1-mo | -45.61% |
| 3-mo | -42.48% |
| 6-mo | -63.79% |
| 1-year | -69.12% |
| 3-year | -73.14% |
| 5-year | N/A |
| YTD | -65.15% |
| 2021 | -63.21% |
| 2020 | 109.07% |
| 2019 | 66.67% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...